These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25403624)

  • 1. Gastrointestinal stromal tumor: 15-years' experience in a single center.
    Wang M; Xu J; Zhang Y; Tu L; Qiu WQ; Wang CJ; Shen YY; Liu Q; Cao H
    BMC Surg; 2014 Nov; 14():93. PubMed ID: 25403624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study.
    Colombo C; Ronellenfitsch U; Yuxin Z; Rutkowski P; Miceli R; Bylina E; Hohenberger P; Raut CP; Gronchi A
    Ann Surg Oncol; 2012 Oct; 19(11):3361-7. PubMed ID: 22843188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.
    Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P
    Eur J Cancer; 2015 May; 51(7):852-60. PubMed ID: 25801699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment--lessons learned.
    Cheng CT; Tsai CY; Yeh CN; Chiang KC; Chen YY; Wang SY; Chen TW; Tseng JH; Jung SM; Chen TC; Yeh TS
    Anticancer Res; 2014 Nov; 34(11):6617-25. PubMed ID: 25368266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence After Resection.
    Guérin A; Sasane M; Keir CH; Gauthier G; Macalalad AR; Wu EQ; Conley AP
    JAMA Oncol; 2015 Sep; 1(6):797-805. PubMed ID: 26204106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroups of patients with very large gastrointestinal stromal tumors with distinct prognoses: a multicenter study.
    Wada N; Kurokawa Y; Nishida T; Takahashi T; Toyokawa T; Kusanagi H; Hirota S; Tsujinaka T; Mori M; Doki Y
    J Surg Oncol; 2014 Feb; 109(2):67-70. PubMed ID: 24155204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
    Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
    Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
    Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10  cm: A Single-Institution Experience in China.
    Shen C; Chen H; Yin Y; Chen J; Tang S; Zhang B; Han L; Chen Z; Chen J
    Medicine (Baltimore); 2015 Jul; 94(28):e1117. PubMed ID: 26181546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
    Wu TJ; Lee LY; Yeh CN; Wu PY; Chao TC; Hwang TL; Jan YY; Chen MF
    BMC Gastroenterol; 2006 Oct; 6():29. PubMed ID: 17062131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of perioperative imatinib mesylate therapy in initial resectable primary local advanced gastrointestinal stromal tumor at intermediate or high risk].
    Li SX; Li ZY; Zhang LH; Bu ZD; Wu AW; Wu XJ; Zong XL; Shan F; Ji X; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):226-9. PubMed ID: 23536340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
    J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.
    Rossi S; Miceli R; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Toffolatti L; Laurino L; Mariani L; Vinaccia V; Gnocchi C; Gronchi A; Casali PG; Dei Tos AP
    Am J Surg Pathol; 2011 Nov; 35(11):1646-56. PubMed ID: 21997685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
    Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
    BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
    Joensuu H; Vehtari A; Riihimäki J; Nishida T; Steigen SE; Brabec P; Plank L; Nilsson B; Cirilli C; Braconi C; Bordoni A; Magnusson MK; Linke Z; Sufliarsky J; Federico M; Jonasson JG; Dei Tos AP; Rutkowski P
    Lancet Oncol; 2012 Mar; 13(3):265-74. PubMed ID: 22153892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New fronts in the adjuvant treatment of GIST.
    Reichardt P; Joensuu H; Blay JY
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
    Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
    Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.